Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

NCT02886494 is registered in ClinicalTrials.gov with Charsire Biotechnology Corp. as lead sponsor.

NCT NCT02886494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02886494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
Lead sponsor
Charsire Biotechnology Corp.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
November 1, 2018
Enrollment
80 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease or vascular dementia